269 related articles for article (PubMed ID: 32428800)
1. Effect of epidermal growth factor receptor mutation on early-stage non-small cell lung cancer according to the 8th TNM classification.
Isaka T; Ito H; Nakayama H; Yokose T; Yamada K; Masuda M
Lung Cancer; 2020 Jul; 145():111-118. PubMed ID: 32428800
[TBL] [Abstract][Full Text] [Related]
2. Effect of epidermal growth factor receptor gene mutation on the prognosis of pathological stage II-IIIA (8th edition TNM classification) primary lung cancer after curative surgery.
Isaka T; Ito H; Nakayama H; Yokose T; Saito H; Adachi H; Miura J; Shigefuku S; Kikuchi A; Rino Y
Lung Cancer; 2021 Dec; 162():128-134. PubMed ID: 34775216
[TBL] [Abstract][Full Text] [Related]
3. The Prognostic Role of PORT and EGFR Mutation Status in Completely Resected Stage IIIA/N2 Non-Small Cell Lung Cancer Patients with Postoperative Chemotherapy.
Yang H; Wang K; Li S; Li Y; Yuan L
Pathol Oncol Res; 2021; 27():1609898. PubMed ID: 34447289
[No Abstract] [Full Text] [Related]
4. Prognostic value of positron emission tomography in resected stage IA non-small cell lung cancer.
Chou HP; Lin KH; Huang HK; Lin LF; Chen YY; Wu TH; Lee SC; Chang H; Huang TW
Eur Radiol; 2021 Oct; 31(10):8021-8029. PubMed ID: 33763721
[TBL] [Abstract][Full Text] [Related]
5. Incorporation of EGFR mutation status into M descriptor of new TNM classification influences survival curves in non-small cell lung cancer patients.
Stanic K; Turnsek N; Vrankar M
Radiol Oncol; 2019 Nov; 53(4):453-458. PubMed ID: 31747381
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of blood and lymphatic vessel invasion in pathological stage IA lung adenocarcinoma in the 8th edition of the TNM classification.
Samejima J; Yokose T; Ito H; Nakayama H; Nagashima T; Suzuki M; Hamanaka R; Yamada K; Masuda M
Lung Cancer; 2019 Nov; 137():144-148. PubMed ID: 31593845
[TBL] [Abstract][Full Text] [Related]
7. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 score as a prognostic biomarker in asian early-stage epidermal growth factor receptor-mutated lung cancer.
Saw SPL; Ng WP; Zhou S; Lai GGY; Tan AC; Ang MK; Lim WT; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Chan JWK; Teh YL; Pang M; Yeo JC; Takano A; Ong BH; Tan EH; Tan SH; Skanderup AJ; Tan DSW
Eur J Cancer; 2023 Jan; 178():139-149. PubMed ID: 36436331
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Effect of Lymphovascular Invasion on TNM Staging in Stage I Non-Small-cell Lung Cancer.
Noma D; Inamura K; Matsuura Y; Hirata Y; Nakajima T; Yamazaki H; Hirai Y; Ichinose J; Nakao M; Ninomiya H; Mun M; Nakagawa K; Masuda M; Ishikawa Y; Okumura S
Clin Lung Cancer; 2018 Jan; 19(1):e109-e122. PubMed ID: 29066222
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.
Isaka T; Ito H; Yokose T; Saito H; Adachi H; Murakami K; Miura J; Kikunishi N; Rino Y
BMC Cancer; 2022 Sep; 22(1):966. PubMed ID: 36085020
[TBL] [Abstract][Full Text] [Related]
11. EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Tang W; Li X; Xie X; Sun X; Liu J; Zhang J; Wang C; Yu J; Xie P
Lung Cancer; 2019 Oct; 136():6-14. PubMed ID: 31421260
[TBL] [Abstract][Full Text] [Related]
12. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer.
Baek MY; Ahn HK; Park KR; Park HS; Kang SM; Park I; Kim YS; Hong J; Sym SJ; Park J; Lee JH; Shin DB; Cho EK
Korean J Intern Med; 2018 Jan; 33(1):168-175. PubMed ID: 27093978
[TBL] [Abstract][Full Text] [Related]
15. Risk stratification and adjuvant chemotherapy after radical resection based on the clinical risk scores of patients with stage IB-IIA non-small cell lung cancer.
Zhai W; Duan F; Li D; Yan Q; Dai S; Zhang B; Wang J
Eur J Surg Oncol; 2022 Apr; 48(4):752-760. PubMed ID: 34620508
[TBL] [Abstract][Full Text] [Related]
16. Validation of prognostic impact of number of extrathoracic metastases according to the eighth TNM classification: a single-institution retrospective study in Japan.
Sakai K; Kuramoto J; Kojima A; Nishimura H; Kuwabara Y; Toda M; Kobayashi Y; Kikuchi S; Hirata Y; Mikami-Saito Y; Mikami S; Kyoyama H; Moriyama G; Gemma A; Uematsu K
Int J Clin Oncol; 2019 Dec; 24(12):1549-1557. PubMed ID: 31452019
[TBL] [Abstract][Full Text] [Related]
17. Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.
Jung HA; Lim J; Choi YL; Lee SH; Joung JG; Jeon YJ; Choi JW; Shin S; Cho JH; Kim HK; Choi YS; Zo JI; Shim YM; Park S; Sun JM; Ahn JS; Ahn MJ; Han J; Park WY; Kim J; Park K
Clin Cancer Res; 2022 Oct; 28(19):4312-4321. PubMed ID: 35838647
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases.
Lee HL; Chung TS; Ting LL; Tsai JT; Chen SW; Chiou JF; Leung HW; Liu HE
Radiat Oncol; 2012 Oct; 7():181. PubMed ID: 23110940
[TBL] [Abstract][Full Text] [Related]
19. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
20. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
